Drug Discovery World

FEBRUARY 7, 2024

For this year’s SLAS2024 conference in Boston (which takes place 3-7 February), DDW’s Megan Thomas narrates articles from the DDW SLAS2024 supplement as part of the DDW Events podcast series. Erin Welsh, PhD, is a disease ecologist and epidemiologist now working full-time as a science communicator.

Science 130

Science Disease Drugs 130

Drug Discovery World

OCTOBER 12, 2023

You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at ACROBiosystems. The post New online event: Innovative advances in neuroscience appeared first on Drug Discovery World (DDW).

Disease 130

Disease Science Drug Development Drugs 130

Drug Discovery World

JULY 1, 2024

Following a trip to Copenhagen, Denmark, DDW’s Megan Thomas reflects on the Novo Nordisk Foundation’s efforts to tackle cardiometabolic diseases. The World Health Organization (WHO) reports that cardiovascular diseases (CVDs) are the leading cause of death globally, stating that an estimated 17.9

Disease 162

Disease International Research Science 162

Drug Discovery World

FEBRUARY 21, 2023

We sought to clarify the impact of previous vaccination on cardiovascular events among people who develop COVID-19 and found that, particularly among those with comorbidities, such as previous MACE, type 2 diabetes, high cholesterol, liver disease, and obesity, there is an association with a lower risk of complications.

Vaccine 130

Vaccine Disease Research Drugs 130

Drug Discovery World

MARCH 15, 2024

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. All doses were well-tolerated and there were no serious adverse events.

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

JUNE 21, 2023

Join DDW for this exclusive free event, Comparing immune-humanized platforms: Which one is best for my application? The event will take place on July 6 at 3PM BST. The post Exclusive event: How to compare immune-humanized platforms appeared first on Drug Discovery World (DDW). which is supported by The Jackson Laboratory.

Immune Response 130

Immune Response Laboratories Regulations Research 130

Drug Discovery World

MAY 15, 2024

Dr Catherine Beech , CEO at Exonate and Dr Pete Adamson , CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Specific numerical values (steps) denote the severity of NPDR, with 47-53 describing the moderately severe disease.

Disease 162

Disease Treatment Therapies Pharmaceuticals 162

Drug Discovery World

DECEMBER 12, 2022

Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. Expert Dr Camila Egidio, PhD, Sr Director, Application Development, LevitasBio will present the event. Camila Egidio. Register here.

RNA 130

RNA Clinical Trials Trials Drugs 130

Drug Discovery World

APRIL 19, 2024

Askbio’s AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson’s disease, was well tolerated with no serious adverse events in a Phase Ib clinical trial. The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado, USA.

Therapies 130

Therapies Disease Clinical Trials Trials 130

Drug Discovery World

JUNE 23, 2023

PTC Therapeutics has shared interim data from the 12-week portion of the PIVOT-HD Phase II study of PTC518 in Huntington’s disease (HD) patients. PTC518 treatment was also demonstrated to be well tolerated, with no treatment-related serious adverse events, no reports of peripheral neuropathy or dose-limiting toxicities.

Disease 130

Disease Trials Treatment Drugs 130

Drug Discovery World

JULY 15, 2022

Single cell and spatial tools from 10x Genomics are designed to deliver powerful, multiomic insights from complex disease samples that enable you to confidently fuel your target identification pipeline with the most promising candidates. The event is hosted by DDW and supported by 10x Genomics. Register for free here.

Science 130

Science Disease 130

Drugs.com

MAY 24, 2024

FRIDAY, May 24, 2024 -- Ozempic provides a wide variety of health benefits for people with kidney disease and type 2 diabetes, a major clinical trial has found. The drug significantly reduces the risk of severe kidney events, heart problems and.

Disease 123

Disease Clinical Trials Trials Drugs 123

Drug Discovery World

APRIL 13, 2023

A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin medication was found to reduce the increased risk of cardiovascular disease among people living with HIV. Adverse drug events observed in the study were like those in the general population taking statin therapy.

Disease 130

Disease Clinical Trials Trials Virus 130

Drug Discovery World

DECEMBER 1, 2022

Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. Director, Application Development, LevitasBio will present the event. The event will take place on December 14, 2022 at 4PM GMT, 8AM PT.

RNA 130

RNA Clinical Trials Drugs Trials 130

Drug Discovery World

MARCH 6, 2023

The post Rhythm Pharmaceuticals buys biotech focused on rare disease appeared first on Drug Discovery World (DDW). Biopharmaceutical subsidiary Rhythm Pharmaceuticals Netherlands has acquired Xinvento, a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI).

Disease 130

Disease Pharmaceuticals Therapies Treatment 130

Drug Discovery World

JULY 3, 2024

No serious adverse events were observed, with minor events, including transient neutropenia and Clostridioides difficile gastroenteritis, experienced but resolved. At 12 months after dosing, the therapy was well tolerated.

Therapies 147

Therapies Clinical Trials Virus Disease 147

Drug Discovery World

JANUARY 30, 2023

Cell and gene therapies (CGT) are transforming the way diseases are treated. The event will cover aspects affecting growth of the CGT market, including how manufacturing technologies are enabling drug development, what these therapies mean for the healthcare market, and the opportunities for developers.

Disease 130

Disease Treatment Therapies Drug Development 130

Drug Discovery World

NOVEMBER 17, 2022

Subcutaneously administered RLYB116 was observed to be generally well-tolerated at the 100mg dose, with mild or moderate adverse events and no drug-related serious adverse events reported. . The post Positive Phase I results for rare disease inhibitor appeared first on Drug Discovery World (DDW).

Disease 130

Disease Pharmacokinetics Treatment Drugs 130

Drug Discovery World

SEPTEMBER 28, 2022

Join DDW for this exclusive free event High resolution electron cryo-microscopy: From membrane proteins to diseases, supported by Thermo Fisher Scientific. . The event will contain a live Q&A. . It will take place on 19 October, 2022, 4PM BST, 8AM PDT. Register free here. . Register here. .

Disease 130

Disease Drugs Research 130

The Pharma Data

DECEMBER 4, 2020

Alzheimer Disease Tied to Adverse Financial Events. 4, 2020 — Alzheimer disease and related dementias (ADRDs) are associated with adverse financial events years prior to clinical diagnosis, according to a study published online Nov. Professional. FRIDAY, Dec. 30 in JAMA Internal Medicine. glaucoma, hip fracture).

Disease 52

Disease International Treatment Research 52

Drug Discovery World

JULY 19, 2023

Eli Lilly has announced positive results of the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.

Disease 130

Disease Trials Clinical Trials Therapies 130

Drug Discovery World

DECEMBER 11, 2023

The US Food and Drug Administration (FDA) has approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD), Casgevy and Lyfgenia. Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited.”

FDA Approval 130

FDA Approval Therapies FDA Disease 130

FDA Law Blog: Biosimilars

MARCH 7, 2024

recognition of Rare Disease Day. NORD’s announcement followed in the footsteps of European rare disease patient organization, Eurodis , who had celebrated the first Rare Disease Day the year before. Time flies when your goal is to support the thirty million people that suffer from rare diseases.

Disease 69

Disease Government FDA Drugs 69

Advarra

FEBRUARY 22, 2024

Assessing and reporting adverse events (AEs) in clinical trials is critical to ensuring the study is as safe as possible and the participants have the most up to date information so they can decide whether to continue their participation in the research study. These responsibilities and reporting requirements are outlined in U.S. regulations.

FDA 52

FDA Clinical Trials Drugs Research 52

Drug Target Review

APRIL 11, 2024

Targeting pathways involved in SMC phenotypic modulation holds promise for developing novel therapeutic approaches for cardiovascular diseases. Can you explain the methodology used to investigate the genetic variants regulating extracellular matrix (ECM) secretion in SMCs, and predict proteins associated with vascular disease?

Disease 58

Disease Engineering Regulations Clinical Research 58

Science Daily: Pharmacology News

FEBRUARY 19, 2024

Researchers have identified a new pathway that contributes to cardiovascular disease associated with high levels of niacin, a common B vitamin previously recommended to lower cholesterol. The team discovered a link between 4PY, a breakdown product from excess niacin, and heart disease.

Disease 95

Disease Production Research 95

Chemical Biology and Drug Design

MAY 11, 2023

The figure depicts the neuroprotective role of crocin in Parkinson's disease. Abstract Parkinson's disease is among the most common forms of neurodegenerative illness, with present treatment being primarily symptomatic and frequently coming with substantial adverse effects.

Disease 100

Disease Research Clinical Trials Treatment 100

Broad Institute

SEPTEMBER 28, 2023

By Allessandra DiCorato September 28, 2023 Credit: Strittmatter Laboratory, Yale University Amyloid beta clusters (red) builds up among neurons (green) in a mouse model of Alzheimer’s disease. The scientists identified a suite of changes in cells unique to the early stages of Alzheimer’s, including some not seen before in animal studies.

Disease 144

Disease Medical Schools Hospitals Research 144

SCIENMAG: Medicine & Health

JANUARY 12, 2024

12, 2024) — The University of Kentucky will mark a decade of raising awareness and continuing its effort to warn women about the dangers of heart disease with the annual Healthy Hearts for Women Symposium. LEXINGTON, Ky. Credit: Peera_Sathawirawong, iStock/Getty Images Plus LEXINGTON, Ky.

Disease 82

Disease 82

Chemical Biology and Drug Design

FEBRUARY 13, 2024

Alzheimer's disease (AD) is a common age-related neurodegenerative brain disorder characterized by the impairment in memory and other cognitive functions. Abstract Alzheimer's disease (AD) is a common age-related neurodegenerative brain disorder characterized by the impairment in memory and other cognitive functions.

Disease 100

Disease Treatment Therapies Research 100

Drug Discovery World

OCTOBER 24, 2022

Watch the webinar High resolution electron cryo-microscopy: From membrane proteins to diseases, supported by Thermo Fisher Scientific. . The event included a live Q&A. The post High resolution electron cryo-microscopy: From membrane proteins to diseases appeared first on Drug Discovery World (DDW).

Disease 100

Disease Drugs Research 100

Broad Institute

FEBRUARY 7, 2024

However, researchers lack efficient ways to explore how these genetic variants are molecularly connected to cardiovascular disease, limiting efforts to develop therapeutics. The team found that a key biological mechanism involved in a rare vascular disease may influence CAD risk.

Disease 106

Disease Hospitals Medical Schools Regulations 106

Drug Discovery World

FEBRUARY 27, 2024

The results support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease. High LDL-C is a major risk factor for coronary heart disease, heart attack, and stroke, and atherosclerosis is the leading cause of disease burden globally.

Vaccine 260

Vaccine Clinical Trials Disease Clinical Development 260

SCIENMAG: Medicine & Health

AUGUST 28, 2023

military veterans with coronary artery disease, suboptimal lipid-lowering therapy was prevalent in the clinical setting. Optimization of statin therapy was projected to produce clinically relevant reductions in the risks of death and cardiovascular events. About The Study: In this study of 111,000 U.S.

Therapies 84

Therapies Disease 84

BMG Labtech

OCTOBER 30, 2023

Cardiovascular disease, a group of disorders of the heart and blood vessels, is the number one cause of death across the world. One disorder in particular, atherosclerotic vascular disease, a chronic inflammatory disease associated with the formation of arterial plaques, is considered the major cause of cardiovascular diseases.

Disease 52

Disease Cell Based Assays Research Drugs 52

Conversations in Drug Development Trends

APRIL 5, 2024

For others, this rare day is aptly the day we honor rare disease communities. Observed annually on the last day of February since 2008, Rare Disease Day has grown into a global movement for raising awareness, promoting research, and advocating for improved access to rare disease treatments and support services.

Disease 52

Disease Clinical Trials Trials Treatment 52

Drug Channels

APRIL 4, 2022

Rare Disease Innovation & Partnering Summit. Hybrid Event May 17-19, 2022 | Boston, MA www.informaconnect.com/rare. Don’t miss the Rare Disease Innovation & Partnering Summit, coming up May 17-19, 2022 in Boston, MA. Visit www.informaconnect.com/rare for further details and to register. d/b/a Drug Channels Institute.

Disease 98

Disease Therapies FDA Trials 98